[Assessment of ovarian reserve during gender affirmation hormone therapy in trans men].

Baseline testosterone and anti-müllerian hormone levels in trans men prior to treatment were within the reference range for biological women.

• Basal testosterone level was 0.58 ng/ml
• Basal anti-müllerian hormone (AMH) level was 2.89 ng/ml
• Both values were described as 'within the range corresponding to biological women'
• Measurements were taken in the early follicular phase using a chemiluminescent method
• Study included 16 participants with a median age of 22.5 years

All trans men achieved testosterone levels within the male reference range after 6 to 12 months of gender-affirming hormone therapy.

• The male population reference range for testosterone used was 3-9 ng/ml
• All 16 individuals reached this range by the time of their semi-annual or annual control
• Baseline testosterone was 0.58 ng/ml, confirming a substantial increase during treatment
• Controls were conducted at 6 to 12 months after initiation of testosterone treatment

No significant differences in anti-müllerian hormone levels were observed before and after 6 to 12 months of testosterone treatment.

• The p-value for the comparison of baseline and post-treatment AMH levels was p = 0.7630
• AMH was measured at baseline and again at the 6 to 12 month control point
• The study noted 'high biological variability' of AMH as a contextual factor
• The prospective study included 16 participants

Gonadotrophins, estradiol, testosterone, and anti-müllerian hormone were measured at baseline in the early follicular phase using a chemiluminescent method.

• Measurements were taken prior to the start of gender-affirming hormone treatment
• The chemiluminescent method was used for all hormone assays
• At the follow-up control, only testosterone and AMH levels were re-determined
• The study was prospective in design with 16 participants meeting inclusion requirements